Advanced Solid Tumours
Conditions
Brief summary
To assess the safety and tolerability of SHR-A1921 in patients with advanced solid tumours, to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and/or recommended phase II dose (RP2D) of SHR-A1921
Interventions
DRUGSHR-A1921
Treatment group: Subjects will receive an intravenous infusion of SHR-A1921 in a dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.
Sponsors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Voluntary participation and written informed consent； 2. Aged 18-75 years (inclusive), males and females; 3. Consents to provide tumor tissue samples; 4. Subjects must have histologically or clinically confirmed advanced and/or metastatic malignancies for which failure of standard treatment or lack of effective standard treatment; 5. At least one measurable lesion according to RECIST v1.1; 6. ECOG score of 0-1; 7. Expected survival ≥ 12 weeks; 8. Adequate bone marrow reserve and organ function ； 9. For female patients of childbearing potential or male patients with partners of childbearing potential who are not sterilized by surgical operations, they are required to use a medically approved contraceptive measure during the study treatment period and within 3 months after the end of the study treatment; For female patients of childbearing potential who are not sterilized by surgical operations, they must have a negative serum HCG test result within 72 h prior to study enrollment; and they must not be in the lactation period;
Exclusion criteria
1. Known and untreated central nervous system (CNS) or leptomeningeal metastases; 2. Macrovascular invasion based on imaging; 3. Cancerous ascites, pleural effusion or pericardial effusion with clinical symptoms; 4. Has a history of a second malignancy; 5. History of immunodeficiency disease or organ transplant; 6. Uncontrolled cardiac diseases or symptoms; 7. Has a history of non-infectious ILD/pneumonitis that required steroids, or has current ILD/pneumonitis; 8. Has a history of active chronic enteritis 6 weeks prior to the initiation of the study treatment or intestinal obstruction, gastrointestinal perforation 3 months prior to the initiation of the study treatment; 9. Has a history of Grade≥2 bleeding 4 weeks prior to the initiation of the study treatment or is current receiving anticoagulation therapy; 10. Subjects with active hepatitis B or active hepatitis C; 11. Subjects who have received systemic anti-tumor treatments 4 weeks prior to the initiation of the study treatment. 12. Has unresolved toxicities from previous anticancer therapy. 13. Has a history of severe hypersensitivity reactions to either the drug substances or inactive ingredients of SHR-A1921; 14. Subjects with other potential factors that may affect the study results or result in the premature discontinuation as determined by the investigator, such as alcoholism, drug abuse, other serious diseases (including mental illness) requiring concomitant treatment, serious laboratory abnormalities, or family or social factors that could affect the safety of the patients.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dose Limited Toxicity (DLT) | 21 Days (first cycle) | — |
| Maximum Tolerable Dose (MTD) | 21 Days (first cycle) | — |
| Recommended phase II dose (RP2D) | Screening up to dose escalation and expansion study completion, appropriately to 1 year | — |
| Adverse Events | Screening up to study completion, an average of 1 year | Incidence and grade of adverse events as assessed by CTCAE v5.0 |
Secondary
| Measure | Time frame |
|---|---|
| Terminal half-life (t1/2) of SHR-A1921、total antibody | Screening up to end of treatment, an average of 1 year |
| Total body clearance (CL) of SHR-A1921、total antibody | Screening up to end of treatment, an average of 1 year |
| Volume of distribution at steady state (Vss) of SHR-A1921、total antibody | Screening up to end of treatment, an average of 1 year |
| Mean residence time (MRT) of SHR-A1921、total antibody | Screening up to end of treatment, an average of 1 year |
| Maximum steady-state drug concentration during a dosage interval (Css, max) of SHR-A1921、total antibody | Screening up to end of treatment, an average of 1 year |
| Minimum steady-state drug concentration during a dosage interval (Css, min) of SHR-A1921、total antibody | Screening up to end of treatment, an average of 1 year |
| Time to reach maximum concentration (Tmax) of SHR-A1921、total antibody | Screening up to end of treatment, an average of 1 year |
| Anti-drug antibody(ADA) level of SHR-A1921 | Screening up to 90 days after the last dose, an average of 1 year |
| Objective Response Rate (ORR) assessed by site investigator as per RECIST 1.1 | Screening up to study completion, an average of 1 year |
| Duration of Response (DoR) assessed by site investigator as per RECIST 1.1 | Screening up to study completion, an average of 1 year |
| Disease Control Rate (DCR) assessed by site investigator as per RECIST 1.1 | Screening up to study completion, an average of 1 year |
| Progression-Free Survival (PFS) assessed by site investigator as per RECIST 1.1 | Screening up to study completion, an average of 1 year |
| Overall Survival (OS) | Screening up to study completion, an average of 1 year |
| Accumulation ratio (Rac) of SHR-A1921、total antibody | Screening up to end of treatment, an average of 1 year |
| Maximum concentration (Cmax) of SHR-A1921、total antibody | Screening up to end of treatment, an average of 1 year |
| Area under the concentration-time curve from time zero to the time of the last quantifiable time point t (AUC0-t) of SHR-A1921、total antibody | Screening up to end of treatment, an average of 1 year |
| Area under the concentration-time curve from time 0 extrapolated to infinity (AUC0-t) of SHR-A1921、total antibody | Screening up to end of treatment, an average of 1 year |
Contacts
Primary ContactQuanren Wang, Ph.D
Backup ContactDi Zong, MS
Outcome results
None listed